Research progress on oxaliplatin-induced peripheral neuropathy

doi:10.16138/j.1673-6087.2025.05.09

Abstract

Abstract:

Oxaliplatin-induced peripheral neuropathy (OIPN) is a common dose-limiting toxic reaction in chemotherapy for gastrointestinal malignancies such as colorectal and gastric cancers, is characterized by sensory abnormalities and pain that substantially impair treatment efficacy and quality of life. This article provides a systematic review of the pathogenesis, diagnostic criteria, contributing factors, and therapeutic strategies of OIPN, aiming to raise clinician’s attention to OIPN and provide a reference for future clinical management in oncological practice.

Key words: Peripheral neuropathy, Oxaliplatin, Pathogenesis, Symptom management

CLC Number:

R746

ZHANG Yi, QIU Xiaoxia. Research progress on oxaliplatin-induced peripheral neuropathy[J]. Journal of Internal Medicine Concepts & Practice, 2025, 20(05): 393-398.

Figures/Tables 1

References 28

[28]	Ren LP, Wang YF, Jiao JB, et al. A pathway analysis of impact of chemotherapy - induced peripheral neuropathy and its predictors on quality of life among cancer patients[J]. Chin J Nurs Educ, 2020, 17(12): 1129-1133. doi: 10.3761/j.issn.1672-9234.2020.12.015
[29]	Yildirim N, Cengiz M. Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin[J]. Support Care Cancer, 2020, 28(10): 4781-4788.
[30]	Lee S, Ma C, Shi Q, et al. Potential mediators of oxaliplatin-induced peripheral neuropathy from adjuvant therapy in stage Ⅲ colon cancer: findings from calgb (alliance)/swog 80702[J]. J Clin Oncol, 2023, 41(5): 1079-1091. doi: 10.1200/JCO.22.01637
[31]	Yang T, Fang Y, Chang L, et al. Central vs. peripheral venous oxaliplatin administration and chemotherapy-induced peripheral neuropathy severity[EB/OL]. Pain Manag Nurs, 2025. https://www.painmanagementnursing.org/article/S1524-9042(25)00202-4/fulltext.
[32]	Yoshino T, Yamanaka T, Oki E, et al. Efficacy and longterm peripheral sensory neuropathy of 3 vs. 6 months of oxaliplatin - based adjuvant chemotherapy for colon cancer: the achieve phase 3 randomized clinical trial[J]. Oncol, 2019, 5(11): 1574-1581.
[33]	Bonhof CS, van de Graaf DL, Wasowicz DK, et al. Symptoms of pre-treatment anxiety are associated with the development of chronic peripheral neuropathy among colorectal cancer patients[J]. Support Care Cancer, 2022, 30(6): 5421-5429.
[34]	Trompetter HR, Bonhof CS, van de Poll-Franse LV, et al. Exploring the relationship among dispositional optimism, health - related quality of life, and CIPN severity among colorectal cancer patients with chronic peripheral neuropathy[J]. Support Care Cancer, 2022, 30(1): 95-104.
[35]	Cavaletti G, Marmiroli P. Management of oxaliplatin-induced peripheral sensory neuropathy[J]. Cancers (Basel), 2020, 12(6): 1370. doi: 10.3390/cancers12061370
[36]	Zhang Z, Ye J, Liu X, et al. Huangqi Guizhi Wuwu decoction alleviates oxaliplatin-induced peripheral neuropathy via the gut-peripheral nerve axis[J]. Chin Med, 2023, 18(1): 114. doi: 10.1186/s13020-023-00826-5
[37]	Chen C, Xu JL, Gu ZC, et al. Danggui Sini decoction alleviates oxaliplatin-induced peripheral neuropathy by regulating gut microbiota and potentially relieving neuroinflammation related metabolic disorder[J]. Chin Med, 2024, 19(1): 58. doi: 10.1186/s13020-024-00929-7
[38]	查荣苹, 刘淑华, 曾梦婷, 等. 化疗诱导的周围神经病变患者多模式运动干预[J]. 护理学杂志, 2023, 38(2): 25-30. doi: 10.3870/j.issn.1001-4152.2023.02.025
	Zha RP, Liu SH, Zeng MT, et al. Effectiveness of multimodal exercise in colorectal cancer patients with chemotherapy - induced peripheral neuropathy[J]. Journal of Nursing Science, 2023, 38(2): 25-30. doi: 10.3870/j.issn.1001-4152.2023.02.025
[1]	Mauri G, Gori V, Bonazzina E, et al. Oxaliplatin retreatment in metastatic colorectal cancer: systematic review and future research opportunities[J]. Cancer Treat Rev, 2020, 91: 102112. doi: 10.1016/j.ctrv.2020.102112
[2]	Balayssac D, Kerckhove N, Selvy M, et al. Motor disorders related to oxaliplatin - induced peripheral neuropathy: long-term severity and impact on quality of life[J]. Support Care Cancer, 2024, 32(7): 427.
[3]	Yang Y, Zhao B, Gao X, et al. Targeting strategies for oxaliplatin - induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development[J]. J Exp Clin Cancer Res, 2021, 40(1): 331. doi: 10.1186/s13046-021-02141-z
[4]	Teng C, Cohen J, Egger S, et al. Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer[J]. Support Care Cancer, 2022, 30(1): 33-47.
[5]	Sittl R, Lampert A, Huth T, et al. Anticancer drug oxaliplatin induces acute cooling - aggravated neuropathy via sodium channel subtype Na(V)1.6 -resurgent and persistent current[J]. Proc Natl Acad Sci U S A, 2012, 109(17): 6704-6709. doi: 10.1073/pnas.1118058109
[6]	Rimola V, Osthues T, Königs V, et al. Oxaliplatin causes transient changes in TRPM8 channel activity[J]. Int J Mol Sci, 2021, 22(9): 4962. doi: 10.3390/ijms22094962
[7]	Huang KM, Leblanc AF, Uddin ME, et al. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice[J]. J Clin Invest, 2020, 130(9): 4601-4606. doi: 10.1172/JCI136796
[8]	Areti A, Yerra VG, Naidu V, et al. Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy[J]. Redox Biol, 2014, 2: 289-295. doi: 10.1016/j.redox.2014.01.006
[9]	Shatunova S, Aktar R, Peiris M, et al. The role of the gut microbiome in neuroinflammation and chemotherapyinduced peripheral neuropathy[J]. Eur J Pharmacol, 2024, 979: 176818. doi: 10.1016/j.ejphar.2024.176818
[10]	Shen S, Lim G, You Z, et al. Gut microbiota is critical for the induction of chemotherapy-induced pain[J]. Nat Neurosci, 2017, 20(9): 1213-1216. doi: 10.1038/nn.4606
[11]	Jordan B, Margulies A, Cardoso F, et al. Systemic anti cancer therapy-induced peripheral and central neurotoxicity: ESMO - EONS - EANO clinical practice guidelines for diagnosis, prevention, treatment and follow - up[J]. Ann Oncol, 2020, 31(10): 1306-1319. doi: 10.1016/j.annonc.2020.07.003
[12]	Li T, Timmins HC, Mahfouz FM, et al. Validity of patientreported outcome measures in evaluating nerve damage following chemotherapy[J]. JAMA Netw Open, 2024, 7(8): e2424139. doi: 10.1001/jamanetworkopen.2024.24139
[13]	Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and management of chemotherapy - induced peripheral neuropathy in survivors of adult cancers[J]. J Clin Oncol, 2020, 38(28): 3325-3348. doi: 10.1200/JCO.20.01399
[14]	Tao Z, Chen Z, Zeng X, et al. An emerging aspect of cancer neuroscience: a literature review on chemotherapy-induced peripheral neuropathy[J]. Cancer Lett, 2024, 611: 217433.
[15]	Argyriou AA, Park SB, Islam B, et al. Neurophysiological, nerve imaging and other techniques to assess chemotherapy - induced peripheral neurotoxicity in the clinical and research settings[J]. J Neurol Neurosurg Psychiatry, 2019, 90(12): 1361-1369.
[16]	Dhage S, Ferdousi M, Adam S, et al. Corneal confocal microscopy identifies small fibre damage and progression of diabetic neuropathy[J]. Sci Rep, 2021, 11(1): 1859. doi: 10.1038/s41598-021-81302-8
[17]	Petropoulos IN, Bitirgen G, Ferdousi M, et al. Corneal confocal microscopy to image small nerve fiber degeneration[J]. Front Pain Res (Lausanne), 2021, 2: 725363. doi: 10.3389/fpain.2021.725363
[18]	Kim SH, Choi MK, Park NY, et al. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy[J]. Sci Rep, 2020, 10(1): 7995. doi: 10.1038/s41598-020-64511-5
[19]	Hua Y, Lv J, Zhang Y, et al. LC-MS-based serum metabolomics analysis and potential biomarkers for oxaliplatin induced neurotoxicity in colorectal cancer[J]. J Pharm Biomed Anal, 2025, 252: 116492. doi: 10.1016/j.jpba.2024.116492
[20]	Lemanska A, Harkin A, Iveson T, et al. The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial[J]. ESMO Open, 2023, 8(6): 102063. doi: 10.1016/j.esmoop.2023.102063
[21]	Mizrahi D, Park SB, Li T, et al. Hemoglobin, body mass index, and age as risk factors for paclitaxel- and oxaliplatin-induced peripheral neuropathy[J]. JAMA Netw Open, 2021, 4(2): e2036695. doi: 10.1001/jamanetworkopen.2020.36695
[22]	卞芸, 丁永娟, 谢芬, 等. 不同营养状态对结直肠癌患者奥沙利铂化疗致周围神经毒性(OIPN)的影响[J]. 中南药学, 2024, 22(1): 30-35. doi: 10.7539/j.issn.1672-2981.2024.01.005
	Bian Y, Ding YJ, Xie F, et al. Effect of different nutritional status on oxaliplatin-induced peripheral neurotoxicity (OIPN) in colorectal cancer patients[J]. Central South Pharmacy, 2024, 22(1): 30-35. doi: 10.7539/j.issn.1672-2981.2024.01.005
[23]	Yanbing L, Zijun L, Hongbo Z, et al. Relationship between BMI and chemotherapy - induced peripheral neuropathy in cancer patients: a dose-response meta-analysis[J]. World J Surg Oncol, 2025, 23(1): 77. doi: 10.1186/s12957-025-03716-2
[39]	Streckmann F, Elter T, Lehmann HC, et al. Preventive effect of neuromuscular training on chemotherapy-induced neuropathy[J]. JAMA Intern Med, 2024, 184(9): 1046-1053. doi: 10.1001/jamainternmed.2024.2354
[40]	Coolbrandt A, Tobback H, Govaerts R, et al. A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system[J]. ESMO Open, 2023, 8(2): 101205. doi: 10.1016/j.esmoop.2023.101205
[41]	吴丽玲, 崔爽, 林慧. 压迫疗法对结直肠腺癌化疗患者奥沙利铂致周围神经病变和心理痛苦的影响[J]. 中国现代医药杂志, 2021, 23(08): 92-95. doi: 10.3969/j.issn.1672-9463.2021.08.028
	Wu LL, Cui S, Lin H. The impact of compression therapy on oxaliplatin-induced peripheral neuropathy and psychological distress in colorectal adenocarcinoma patients undergoing chemotherapy[J]. MMJC, 2021, 23(08): 92-95. doi: 10.3969/j.issn.1672-9463.2021.08.028
[42]	Huang MC, Chang SC, Liao WL, et al. Acupuncture may help to prevent chemotherapy - induced peripheral neuropathy[J]. Oncologist, 2023, 28(6): e436-e447. doi: 10.1093/oncolo/oyad065
[43]	周岩, 田乃菊, 赵玮璿, 等. 当归四逆汤合身痛逐瘀汤联合艾灸治疗化疗后周围神经病变的临床疗效观察[J]. 辽宁中医杂志, 2025, 52(06): 143-147. doi: 10.13192/j.issn.1000-1719.2025.06.037
	Zhou Y, Tian NJ, Zhao WR, et al. Clinical efficacy of Danggui Sini decoction with Shentong Zhuyu decoction combined with moxa - moxibustion in treating chemotherapy-induced peripheral neuropathy[J]. Liaoning Journal of Traditional Chinese Medicine, 2025, 52(06): 143-147. doi: 10.13192/j.issn.1000-1719.2025.06.037
[44]	D'Souza RS, Her YF, Jin MY, et al. Neuromodulation therapy for chemotherapy-induced peripheral neuropathy[J]. Biomedicines, 2022, 10(8): 1909. doi: 10.3390/biomedicines10081909
[45]	张冉, 甘宇, 冯艺, 等. 迷走神经电刺激对化疗诱发周围神经病变有短期治疗作用[J]. 中国疼痛医学杂志, 2020, 26(05): 337-343. doi: 10.3969/j.issn.1006-9852.2020.05.004
	Zhang R, Gan Y, Feng Y, et al. Electrical stimulation of vagus nerve produces a short - term inhibitory effect on chemotherapy - induced peripheral neuropathy[J]. Chinese Journal of Pain Medicine, 2020, 26(05): 337-343. doi: 10.3969/j.issn.1006-9852.2020.05.004
[46]	Gewandter JS, Culakova E, Davis JN, et al. Wireless Transcutaneous electrical nerve stimulation (tens) for chronic chemotherapy - induced peripheral neuropathy (cipn)[J]. J Pain, 2024, 25(5): 104431. doi: 10.1016/j.jpain.2023.11.014
[24]	Compton SLE, Yang S, Madere J, et al. Dietary quality and chemotherapy-induced peripheral neuropathy in colon cancer[J]. Cancer, 2025, 131(1): e35599. doi: 10.1002/cncr.35599
[25]	胜芙蓉. 化疗药物致周围神经病变风险与糖尿病相关性的研究[D]. 2019. 沈阳: 中国医科大学.
	Sheng FR. Study on the relationship between the risk of chemotherapy-induced peripheral neuropathy and diabetes[D]. 2019. Shenyang: China Medical University.
[26]	魏小清, 林捷如, 叶芳, 等. 奥沙利铂致周围神经病变风险预测模型的构建及应用[J]. 现代医药卫生, 2022, 38(9): 1479-1482.
	Wei XQ, Lin JR, Ye F, et al. Construction and application of risk prediction model of oxaliplatin induced peripheral neuropathy[J]. J Mod Med Health, 2022, 38(9): 1479-1482.
[27]	Kleckner IR, Kamen C, Gewandter JS, et al. Effects of exercise during chemotherapy on chemotherapy - induced peripheral neuropathy: a multicenter, randomized controlled trial[J]. Support Care Cancer, 2018, 26(4): 10191028.
[28]	任丽萍, 王永芳, 焦俊博, 等. 癌症患者化疗致周围神经病变及相关因素对生活质量的影响[J]. 中华护理教育, 2020, 17(12): 1129-1133. doi: 10.3761/j.issn.1672-9234.2020.12.015

特性	急性OIPN	慢性OIPN
发生率	4%~95%	30%~50%
时间窗	通常在输注几小时内出现，持续数天	常于累积剂量达540 mg/m²后发生，持续数月或数年
关键分子机制	钠、钾离子通道功能异常；瞬时受体电位通道异常；有机阳离子转运蛋白过表达	核DNA损伤；线粒体功能障碍；氧化应激与神经炎症；胶质细胞激活；肠道菌群失调
典型症状	寒冷诱发的感觉异常（如手脚或口周刺痛）；肌肉痉挛；咽部感觉不良	持续性感觉减退或异常（如麻木、套袜感）；神经性疼痛（灼烧、电击感）；感觉性共济失调（如平衡障碍）